ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

The results of a clinical trial led by researchers at the University of Arizona Health Sciences and published in the Journal ...

JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer ...

FOR the 6,000 people in the UK who are newly diagnosed with bile duct cancer every year, the prognosis is uniquely grim.

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

A Keighley deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

A KEIGHLEY deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

Raritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

Despite a big increase in “watchful waiting” in the past 15 years, there’s a new study from the U.S. Department of Veterans Affairs health system shows that overtreatment of prostate cancer persists.

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...